Clinical Trial

Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and clinical ILD in patients with early lupus.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-21.
Status change: Enrolling by Invitation → Recruiting 2026-01-25
Trial Details
NCT Number NCT07077486
Lead Sponsor Tongji Hospital
Collaborators: Wuhan Central Hospital, Wuhan Hospital of Traditional Chinese Medicine, Rongchang Biopharmaceutical, Johns Hopkins Bloomberg School of Public Health
Conditions Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus
Enrollment 100 participants
Start Date 2025-08-25
Primary Completion 2026-10-25 (estimated)
Study Completion 2027-03-25 (estimated)
Updated on ClinicalTrials.gov 2026-01-27